Orexo Past Earnings Performance
Past criteria checks 0/6
Orexo's earnings have been declining at an average annual rate of -38.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 6.4% per year.
Key information
-38.8%
Earnings growth rate
-38.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -6.4% |
| Return on equity | n/a |
| Net Margin | -17.7% |
| Next Earnings Update | 06 Feb 2025 |
Recent past performance updates
Recent updates
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Dec 20
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 05Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Revenue & Expenses Breakdown
How Orexo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 596 | -105 | 269 | 243 |
| 30 Jun 24 | 615 | -97 | 280 | 270 |
| 31 Mar 24 | 619 | -73 | 272 | 281 |
| 31 Dec 23 | 639 | -128 | 306 | 303 |
| 30 Sep 23 | 629 | -201 | 380 | 326 |
| 30 Jun 23 | 634 | -195 | 347 | 319 |
| 31 Mar 23 | 624 | -218 | 362 | 325 |
| 31 Dec 22 | 624 | -178 | 325 | 318 |
| 30 Sep 22 | 612 | -152 | 330 | 310 |
| 30 Jun 22 | 597 | -177 | 348 | 297 |
| 31 Mar 22 | 592 | -216 | 350 | 289 |
| 31 Dec 21 | 565 | -223 | 372 | 272 |
| 30 Sep 21 | 580 | -207 | 374 | 251 |
| 30 Jun 21 | 585 | -240 | 409 | 238 |
| 31 Mar 21 | 621 | -198 | 408 | 228 |
| 31 Dec 20 | 664 | -84 | 389 | 225 |
| 30 Sep 20 | 743 | 4 | 368 | 225 |
| 30 Jun 20 | 824 | 201 | 322 | 216 |
| 31 Mar 20 | 846 | 288 | 341 | 197 |
| 31 Dec 19 | 845 | 219 | 332 | 181 |
| 30 Sep 19 | 834 | 232 | 413 | 170 |
| 30 Jun 19 | 819 | 182 | 421 | 166 |
| 31 Mar 19 | 818 | 178 | 364 | 159 |
| 31 Dec 18 | 783 | 138 | 358 | 167 |
| 30 Sep 18 | 747 | 113 | 275 | 156 |
| 30 Jun 18 | 697 | 79 | 268 | 147 |
| 31 Mar 18 | 656 | 32 | 274 | 149 |
| 31 Dec 17 | 644 | 23 | 287 | 134 |
| 30 Sep 17 | 637 | 19 | 230 | 133 |
| 30 Jun 17 | 653 | 27 | 256 | 128 |
| 31 Mar 17 | 682 | 29 | 303 | 118 |
| 31 Dec 16 | 706 | 29 | 324 | 132 |
| 30 Sep 16 | 752 | -57 | 419 | 154 |
| 30 Jun 16 | 710 | -139 | 434 | 173 |
| 31 Mar 16 | 648 | -229 | 430 | 183 |
| 31 Dec 15 | 646 | -210 | 439 | 173 |
| 30 Sep 15 | 636 | -95 | 412 | 164 |
| 30 Jun 15 | 627 | -85 | 389 | 173 |
| 31 Mar 15 | 617 | -51 | 357 | 185 |
| 31 Dec 14 | 570 | -57 | 307 | 198 |
| 30 Sep 14 | 449 | -146 | 299 | 197 |
| 30 Jun 14 | 440 | -138 | 288 | 208 |
| 31 Mar 14 | 391 | -204 | 252 | 239 |
| 31 Dec 13 | 429 | -155 | 251 | 238 |
Quality Earnings: ORX is currently unprofitable.
Growing Profit Margin: ORX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORX is unprofitable, and losses have increased over the past 5 years at a rate of 38.8% per year.
Accelerating Growth: Unable to compare ORX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: ORX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 01:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orexo AB (publ) is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Klas Palin | Carnegie Commissioned Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |